Navigation Links
Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting
Date:4/30/2009

>

AFP464 is nearing completion of Phase I clinical testing at Jules Bordet Institute in Belgium, Institut Gustav Roussy in Paris, Mayo Clinic in Rochester, Minnesota, Karmanos Cancer Institute in Detroit and University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore. Tigris Pharmaceuticals expects to soon move to Phase II clinical studies, including studies in triple-negative breast cancer patients with the drug alone or in combination with vorinostat, depending on the molecular gene profile subtypes of the patients. Triple-negative breast cancer afflicts mostly young women under the age of 40 and is more prevalent in the African-American and Hispanic community. About 182,460 women in the United States were diagnosed with invasive breast cancer in 2008, approximately 15-18% of which are triple negative, and about 40,480 will die from the disease, according to the American Cancer Society.

"Patients with triple negative breast cancer do not benefit from endocrine therapy or molecularly targeted therapy such as trastuzumab because they lack the targets for these drugs," said Dr. Binh Nguyen, M.D., Ph.D., Chief Medical Officer of Tigris. "The potential of using molecular gene profile to target the appropriate patient population that most likely could benefit from the treatment with AFP-464 is the right direction in the clinical development of this difficult to treat disease."

About AFP-464

AFP-464, a Lysol prodrug of aminoflavone (AF), undergoes rapid conversion to AF by nonspecific plasma esterases. It has shown a unique pattern of growth inhibitory activity in the NCI's 60 tumor cell line screen, with breast, ovarian, lung and renal lines exhibiting particular sensitivity. The mechanism of action of AF is believed to be that treatment with AF results in translocation of the arylhydrocarbon receptor (AhR; a transcriptional regulator of CYP1A1) from the cytoplasm to the nucleus,
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceuticals GGTI-2418
2. Tigris Pharmaceuticals Files IND Application for GGTI-2418
3. Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
4. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Onyx Pharmaceuticals Announces First Quarter 2009 Financial Results Teleconference and Webcast
7. Transcept Pharmaceuticals to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
8. Inimex Pharmaceuticals begins First Clinical Study of an Innate Defense Regulator
9. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
10. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Malvern, PA & Brussels (PRWEB) December 22, 2014 ... Education (CfPIE), the global leader of technical training ... Society for Clinical Data Management (SCDM) to ... training and certification programs —providing access to the ... The partnership extends SCDM members with 10% off when ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... and editorials addressing developments and pathways related to ... provocative article exploring the role of follicle-stimulating hormone ... of prostate cancer. , The article references ... that there could be a connection to prostate ...
(Date:12/19/2014)... Tigard, OR and Hershey, PA (PRWEB) December 19, ... (OTC Pink: BJCT), a leading developer and manufacturer ... has entered into an agreement with Immunomic Therapeutics, ... Bioject’s Biojector®-2000 needle-free injection device with its LAMP™ ... receives an option for an exclusive Worldwide license ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... 13, 2011 PrimeraDx today announced that Jeff Liter ... Development.   "Jeff,s diverse background in all ... to the leadership team," Said Matt McManus, President and ... capabilities of the ICE Plex system in the ...
... a human gene mutation in a patient,s stem cells. ... 12 October, brings the possibility of patient-specific therapies closer ... researchers from the Wellcome Trust Sanger Institute and the ... both cirrhotic liver disease and lung emphysema. Using cutting-edge ...
... Life Technologies Corporation (NASDAQ: LIFE ) ... Sequencing 200 Kit, which enables 200 base pair reads. The ... sequencer that can deliver millions of highly accurate long reads ... after our launch, the speed, simplicity and scalability of ...
Cached Biology Technology:PrimeraDx Appoints Jeff Liter as VP of Corporate Development 2Clean correction of a patient's genetic mutation 2Clean correction of a patient's genetic mutation 3Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 2Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 3Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 4Ion Torrent Gets Better Faster With 4th Qtr New Product Releases 5
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... You,ve been here before: you desperately need to sign into ... key or the answer to your secret question. What,s your ... Today, Hoyos Labs , a digital infrastructure security ... an end to the frustration that comes with usernames, passwords ... a user,s smartphone to acquire his or her biometrics to ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Microbes are everywhere thousands of species are in your mouth, ... in your mouth are mostly harmless as long as you ... gum disease a path into the blood stream. Microbes in ... country are also mostly harmless with some notable exceptions. ...
... from the National Cancer Centre Singapore, Duke-NUS Graduate Medical ... University (Thailand), have made a seminal breakthrough in understanding ... a rare but highly lethal form of liver cancer. ... Tan, Steve Rozen, Irinel Popescu and Vajaraphongsa Bhudhisawasdi, used ...
... the first conference of its 2013-2014 meeting season and ... "Advancing Vaccines in the Genomics Era" at the Windsor ... Grand Challenges in Global Health meeting for that program,s ... Symposia Global Health Series, supported by the Bill & ...
Cached Biology News:Virginia Tech researchers explore natural way to displace harmful germs from household plumbing 2Virginia Tech researchers explore natural way to displace harmful germs from household plumbing 3Virginia Tech researchers explore natural way to displace harmful germs from household plumbing 4Singapore scientists expose molecular secrets of bile duct cancers from different countries 2Singapore scientists expose molecular secrets of bile duct cancers from different countries 3Keystone Symposia launches 2013-14 meeting series with first conference in Rio de Janeiro 2
... These plastic feeding tubes for rodent ... reduce the risk of perforation and trauma. ... hassle of cleaning and the risk of ... 20ga ...
Barcoded Slides, 5 Packs of 5 Slides (25/Case)...
...
... the 9, 10, 12, and 13 positions. It ... for the quantification of 13(S)-HODE by GC- or ... linoleic acid with plant and mammalian lipoxygenases. It ... tumor cells to the endothelium at concentrations around ...
Biology Products: